Signaturefd LLC Raises Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Signaturefd LLC boosted its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) by 61.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 57,466 shares of the company’s stock after buying an additional 21,807 shares during the quarter. Signaturefd LLC’s holdings in AbCellera Biologics were worth $168,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. JPMorgan Chase & Co. increased its position in shares of AbCellera Biologics by 6.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 355,747 shares of the company’s stock valued at $925,000 after purchasing an additional 21,483 shares during the last quarter. State Street Corp increased its position in shares of AbCellera Biologics by 1.5% during the 3rd quarter. State Street Corp now owns 323,229 shares of the company’s stock valued at $840,000 after purchasing an additional 4,679 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of AbCellera Biologics during the 3rd quarter valued at about $668,000. Moloney Securities Asset Management LLC purchased a new stake in shares of AbCellera Biologics during the 4th quarter valued at about $265,000. Finally, HighTower Advisors LLC increased its position in shares of AbCellera Biologics by 577.9% during the 4th quarter. HighTower Advisors LLC now owns 71,086 shares of the company’s stock valued at $208,000 after purchasing an additional 60,600 shares during the last quarter. Hedge funds and other institutional investors own 61.42% of the company’s stock.

Wall Street Analyst Weigh In

ABCL has been the subject of several research reports. Stifel Nicolaus reduced their price target on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 28th. KeyCorp reduced their price target on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a research note on Monday, March 3rd.

AbCellera Biologics Trading Up 2.5 %

Shares of NASDAQ:ABCL opened at $2.44 on Friday. The stock has a 50 day moving average of $2.90 and a 200 day moving average of $2.82. The company has a market cap of $727.09 million, a PE ratio of -4.00 and a beta of 0.45. AbCellera Biologics Inc. has a 12-month low of $2.11 and a 12-month high of $4.75.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.